Anixa Secures Korean Patent for Breast Cancer Vaccine Through 2040 — Anixa Biosciences, Inc.

Event summary

Anixa Biosciences received Patent Number 10-2960889 from the Korean MOIP for its breast cancer vaccine technology, valid through 2040.
The patent covers a composition-of-matter claim licensed exclusively from Cleveland Clinic.
Breast cancer incidence rates are rising in South Korea, particularly among younger women.
Anixa's Phase 1 clinical trial showed the vaccine was safe and generated immune responses in 74% of participants.

The big picture

Anixa's patent win in South Korea strengthens its global IP estate for a preventive breast cancer vaccine, an area with no approved solutions worldwide. The move aligns with rising incidence rates in key markets like South Korea, where earlier-onset cases heighten demand for preventive options. This strategic expansion positions Anixa to pursue international regulatory approvals and partnerships as it advances clinical development.

What we're watching

Regulatory Pathways: How Anixa will leverage this patent to pursue regulatory approvals in South Korea and other international markets.
Partnership Potential: Whether the expanded IP protection will attract larger pharmaceutical companies for global commercialization partnerships.
Clinical Development: The pace at which Anixa advances its breast cancer vaccine through subsequent clinical trials in the U.S. and internationally.